Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Windtree Therapeutics's pretax income for the
three
months ended in Sep. 2025 was $-31.52 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2025 was $-43.50 Mil.
Windtree Therapeutics's pretax margin was %.
During the past 13 years, Windtree Therapeutics's highest Pretax Margin was -1148.38%. The lowest was -13876.26%. And the median was -1933.89%.
During the past 13 years, Windtree Therapeutics's highest Pretax Margin was -1148.38%. The lowest was -13876.26%. And the median was -1933.89%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics Pre-Tax Income Related Terms
Windtree Therapeutics Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Windtree Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WINT vs LIPO, ITRMF, IOBTQ: Pre-Tax Income Comparison
For the Biotechnology subindustry, Windtree Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics (WINT) has a Pre-Tax Income of $-43.50 Mil as of Sep. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Windtree Therapeutics and its competitors.
Is Windtree Therapeutics' Pre-Tax Income too high?
Windtree Therapeutics' current Pre-Tax Income is $-43.50 Mil.
How does Windtree Therapeutics' Pre-Tax Income compare to LIPO and ITRMF?
Windtree Therapeutics' Pre-Tax Income of $-43.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Windtree Therapeutics and its competitors. Windtree Therapeutics's current Pre-Tax Income is $-43.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Pre-Tax Income of $-43.50 Mil. The current Pre-Tax Income is $-43.50 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Pre-Tax Income is $-43.50 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
